Skip to main content

Table 2 Univariable cox analysis of risk factors for early recurrence of HCC

From: Preoperative risk stratification for early recurrence of HBV-related hepatocellular carcinoma after deceased donor liver transplantation: a five-eight model development and validation

Variable2-year recurrence rateHRSEzP > z95% CI
Age (52/≤52 years)17.6/16.40.980.250.070.9420.59–1.63
Gender (male/female)17.9/9.21.510.780.800.4260.55–4.16
Diabetes (yes/no)19.4/17.10.790.340.550.5850.34–1.84
Hypertension (yes/no)24.7/16.31.540.591.140.2530.73–3.25
BMI (25/≤25)18.5/16.40.990.280.050.9590.561.73
CTP class(A/B/C)19.5/14.9/15.30.940.160.380.7050.67–1.31
MELD (12/≤12)13.7/20.20.810.210.810.4160.49–1.35
Cirrhosis (yes/no)17.414.21.240.470.570.5660.59–2.62
Pre-LT AFP (ng/mL) (Reference, ≤10)
 10–20019.53.571.652.750.0061.44–8.83
 201–100021.84.652.293.110.0021.77–12.23
  > 100039.29.034.204.72< 0.0013.62–22.49
Total tumor diameter (cm) (Reference, ≤5)
 5–821.93.201.193.130.0021.55–6.64
  > 852.68.892.886.75< 0.0014.7116.76
Largest tumor diameter (cm) (Reference, ≤4)
 4–621.82.370.902.280.0231.13–4.98
 6–828.23.671.553.080.0021.61–8.39
  > 874.810.493.317.45< 0.0015.65–19.46
Nodules number (single/multiple)12.3/24.61.883142.48742332.450.0141.13–3.13
Pre-LT TACE (yes/no)23.3/13.02.030.532.730.0061.22–3.39
Pre-LT RFA (yes/no)13.6/18.00.790.290.650.5190.39–1.61
Pre-LT hepatectomy (yes/no)25.0/15.51.590.491.520.1280.88–2.90
Vascular invasion (yes/no)43.0/9.84.311.125.62< 0.0012.59–7.17
Differentiation (Reference, well)
 moderate14.91.520.670.950.3440.64–3.59
 poor26.12.811.352.160.0311.10–7.19
 Milan criteria (out/in)33.8/4.87.682.785.64< 0.0013.78–15.62
 Hangzhou criteria (out/in)57.5/9.17.241.917.52< 0.0014.32–12.13
 AFP model (out/in)35.0/7.95.801.735.89< 0.0013.23–10.41
  1. Note: BMI Body mass index, CTP Child-Turcotte-Pugh, AFP Alpha-fetoprotein, MELD Model for End-Stage Liver Disease, LT Liver transplantation, TACE Transarterial chemoembolization, RFA Radiofrequency ablation